



## MONITORER CLINIQUE

### Mortality and Functional Morbidity After Use of PALS/APLS by Community Physicians



### Mortality and Functional Morbidity After Use of PALS/APLS by Community Physicians



## MONITORER CLINIQUE

than 150 beats/min (73). Emergency department therapies should be directed toward restoring normal mental status, threshold HRs, peripheral perfusion (capillary refill < 3 s), palpable distal pulses, and blood pressure for age (10). Carillo

### American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock

#### **Stabilization: Beyond the First Hour (NICU Hemodynamic Support)**

Goals: (Level 1C)


- Restore and maintain threshold HR.
- Maintain normal perfusion and blood pressure.
- Maintain neonatal circulation.
- Scvo<sub>2</sub> greater than 70%
- CI greater than 3.3 L/min/m<sup>2</sup>
- SVC flow greater than 40 mL/kg/min

CCM 2017

L Dupic JPU 2107

## MONITORER CLINIQUE


### Définir Choc froid ou Choc chaud



L Dupic JPU 2107

## MONITORING HEMODYNAMIQUE

L Dupic JPU 2107




L Dupic JPU 2107

Invasive Care Med (2013) 39:1602–1609  
DOI 10.1007/s00393-013-3903-z

PEDIATRIC ORIGINAL

Alash Deep  
Chulamanda D. A., Gunasekera  
Yanzhong Wang  
Joe Brierley

### Evolution of haemodynamics and outcome of fluid-refractory septic shock in children



Int Care Med 2013

L Dupic JPU 2107

### Multimodal Monitoring for Hemodynamic Categorization and Management of Pediatric Septic Shock: A Pilot Observational Study\*

Sachitra Ranji, MD; FCCM<sup>1</sup>; Granam Aram, MD; FNP<sup>2</sup>; Nitinian Klosson, MBBS, FAAP; FCCM<sup>3</sup>; Mbd Kashif Ali, MD<sup>4</sup>; Rajeshwari Natraj, FNP<sup>5</sup>; Sharad Shresti, MD<sup>6</sup>; Indira Jayakumar, DCH, DNB<sup>7</sup>; Deepika Gandhi, DNP<sup>8</sup>

| Table 2. Clinical, Hemodynamic, and Perceived Echocardiography in Patients With Fluid Refractory Shock |   |                |             |                |             |                  |             |        |
|--|---|----------------|-------------|----------------|-------------|------------------|-------------|--------|
| Echocardiographic Findings   |   | Cardiac Output |             | Wet Shock (n)  |             | Normal Shock (n) |             | Normal |
| Perfusion BP after first hour fluid  |   | Normal SBP (n) | Low SBP (n) | Normal SBP (n) | Low SBP (n) | Normal SBP (n)   | Low SBP (n) | Normal |
| Cardiac output < expected by COHO and arterial waveform  |   | ↓              | ↓           | ↓              | ↓           | ↓                | ↓           | ↓      |
| Arterial pressure < 90 mmHg or systolic drop > 10 mmHg/hour  |   | ↓              | ↓           | ↓              | ↓           | ↓                | ↓           | ↓      |
| Decreased urine output < 0.5 mL/kg/hour or oliguria  |   | ↓              | ↓           | ↓              | ↓           | ↓                | ↓           | ↓      |
| ICU mortality > 50%  | 4 | 4              | 2           | 8              | 10          | 4                | 10          | 40     |
| ICU mortality all-cause  | 7 | 6              | 15          | 4              | 22          | 7                | 15          | 40     |
| ICU mortality all-cause < 24 hours   | 7 | 6              | 15          | 4              | 22          | 7                | 15          | 40     |
| Cardiac function   |   | ↓              | ↓           | ↓              | ↓           | ↓                | ↓           | ↓      |
| Improved left ventricular contractility  | 4 | 3              | 11          | 4              | 16          | 4                | 11          | 16     |
| Decreased left ventricular contractility   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Decreased left ventricular contractility < 24 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 24 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 48 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 72 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 96 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 120 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 144 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 168 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 192 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 240 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 288 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 336 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 384 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 432 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 480 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 528 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 576 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 624 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 672 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 720 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 768 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 816 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 864 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 912 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 960 hours  | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1008 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1056 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1104 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1152 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1200 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1248 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1296 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1344 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1392 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1440 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1488 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1536 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1584 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1632 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1680 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1728 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1776 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1824 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1872 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1920 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 1968 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2016 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2064 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2112 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2160 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2208 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2256 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2304 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2352 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2400 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2448 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2496 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2544 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2592 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2640 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2688 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2736 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2784 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2832 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2880 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2928 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 2968 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3008 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3048 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3088 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3128 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3168 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3208 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3248 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3288 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3328 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3368 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3408 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3448 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3488 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3528 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3568 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3608 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3648 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3688 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3728 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3768 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3808 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3848 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3888 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3928 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 3968 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4008 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4048 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4088 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4128 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4168 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4208 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4248 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4288 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4328 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4368 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4408 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4448 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4488 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4528 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4568 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4608 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4648 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4688 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4728 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4768 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4808 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4848 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4888 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4928 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 4968 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5008 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5048 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5088 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5128 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5168 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5208 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5248 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5288 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5328 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5368 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5408 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5448 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5488 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5528 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5568 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5608 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5648 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5688 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5728 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5768 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5808 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5848 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5888 hours   | 7 | 5              | 11          | 6              | 28          | 7                | 11          | 28     |
| Normal or improved LVEF < 5928 hours   |   |                |             |                |             |                  |             |        |

Persistent low microcirculatory vessel density in nonsurvivors of sepsis in pediatric intensive care\*

Anke P. C. Top, MD; Can Ince, PhD; Neelke de Meij, MD; Monique van Dijk, PhD; Dick Tibboel, PhD

Table 3. Microvascular flow index on day 1, 2, and 3

| MTI    | Survivors         |                   |                   | Nonsurvivors     |                  |                  |
|--------|-------------------|-------------------|-------------------|------------------|------------------|------------------|
|        | Day 1<br>(n = 15) | Day 2<br>(n = 15) | Day 3<br>(n = 10) | Day 1<br>(n = 3) | Day 2<br>(n = 3) | Day 3<br>(n = 3) |
| Large  | 2.13 (0.67–3.00)  | 2.83* (0.00–3.00) | 2.71* (2.13–3.00) | 2.75 (1.63–3.00) | 2.50 (1.82–3.00) | 2.45 (2.40–2.50) |
| Median | 1.92 (0.84–2.5)   | 2.62* (0.62–3.00) | 2.44 (1.25–3.00)  | 2.38 (0.75–3.00) | 2.00 (1.25–2.33) | 1.28 (0.86–2.20) |
| Small  | 2.00 (0.77–2.77)  | 2.83* (0.00–3.00) | 2.64* (1.67–3.00) | 2.75 (1.63–3.00) | 2.17 (0.70–3.00) | 1.08 (0.50–2.00) |


\*90% microvascular flow index.

\*Significantly different from day 1 ( $p < .05$ ); \*significantly different from survivors on the same day ( $p < .05$ ). Data are presented as median and range.

Evaluation par méthode NIRS (Near Infrared Spectroscopy)

Tests d'occlusion artérielle

- Mesure de la saturation tissulaire en oxygène StO<sub>2</sub>(cerveau, rein, muscle)
- Lumière de proche infrarouge (680–800 nm)
- Absorption différente entre Hb-O<sub>2</sub> et DesO<sub>2</sub>-Hb
- Analysé des Microvaisseaux de manière indifférenciée
- StO<sub>2</sub> musculaire moyenne = 87 ± 6 %
- Evaluation au niveau des muscles l'éminence thénar



L Dupic SRLF 2017


L Dupic JPU 2107

Intensive Care Med (2007) 33:1549–1556

DOI 10.1007/s0034-007-0739-3  
Jacques Creteur  
Tiziana Carollo  
Günther Gattner  
Gustavo Bouček  
Daniel De Backer  
Jean-Louis Vincent


ORIGINAL

The prognostic value of muscle StO<sub>2</sub> in septic patients




L Dupic JPU 2107

COUPLAGE HEMODYNAMIQUE




L Dupic JPU 2107

MONITORING METABOLIQUE




L Dupic JPU 2017



J. Clin. Monit. Comput. Mayevsky 2013

L Dupic SRLF 2017



## DO<sub>2</sub>/VO<sub>2</sub>



## SvO<sub>2</sub>

- La SvO<sub>2</sub> permet une approche globale des déterminants essentiels de l' oxygénation tissulaire, à savoir:
  - Le taux d' hémoglobine
  - L' oxygénation artérielle mesurée par la SaO<sub>2</sub>
  - Le débit cardiaque
  - La consommation en oxygène, ou VO<sub>2</sub>
- Elle est un témoin du rapport entre apport et consommation d' oxygène.

L Dupic JPU 2107



Int Care Med 2008

L Dupic JPU 2107

**Early Goal-Directed Therapy in Pediatric Septic Shock: Comparison of Outcomes "With" and "Without" Intermittent Superior Venacaval Oxygen Saturation Monitoring: A Prospective Cohort Study\***

Sankar, Jhuma MD1; Sankar, M, Jeeva DM2; Suresh, C. P. MD1; Dubey, Nandkishore K. MD1; Singh, Archana MD1

Measurements an25 patients . 125 children were enrolled in the study–63 in the ScvO<sub>2</sub> group and 57 in the no ScvO<sub>2</sub> group. Baseline characteristics including the organ dysfunction and mortality risk scores were comparable between the groups. Children in the ScvO<sub>2</sub> group had significantly lower in-hospital mortality (33.3% vs 54%; relative risk, 0.61; 95% CI, 0.4, 0.93; number needed to treat, 5; 95% CI, 3, 27).

**Conclusion:**  
Early goal-directed therapy using intermittent ScvO<sub>2</sub> monitoring seemed to reduce the mortality rates and improved organ dysfunction in children with septic shock as compared with those without such monitoring.

PCCM 2014

L Dupic JPU 2017

**American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock**


### Stabilization: Beyond the First Hour (NICU Hemodynamic Support)

**Goals: (Level 1C)**

- Restore and maintain threshold HR.
- Maintain normal perfusion and blood pressure.
- Maintain neonatal circulation.
- ScvO<sub>2</sub> greater than 70%
- CI greater than 3.3 L/min/m<sup>2</sup>
- SVC flow greater than 40 mL/kg/min

CCM 2017

L Dupic JPU 2017



L Dupic JPU 2107

## Lactate clearance as the predictor of outcome in pediatric septic shock

Richa Choudhary, Sadasivan Sitaraman, and Anita Choudhary

|                                  | Survivors<br>(n=54) | Nonsurvivors<br>(n=94) | P       |
|----------------------------------|---------------------|------------------------|---------|
| Age* (months)                    | 76.9±51.03          | 43.73±46.76            | <0.0001 |
| Gender, n (%)                    |                     |                        |         |
| Male                             | 33 (61.1)           | 58 (61.7)              | 0.92    |
| Female                           | 21 (38.9)           | 36 (38.3)              |         |
| Duration of illness† (days)      | 5.5 (9.0)           | 4 (4.5)                | <0.0001 |
| Glasgow Coma Scale‡              | 10 (2-14)           | 6 (0-8)                | <0.0001 |
| Mechanical ventilation required  | 13                  | 94                     | 0.0001  |
| Duration of hospital stay‡ (day) | 12 (8-15)           | 5 (3-9)                | <0.0001 |
| TLC* (ml/mm <sup>2</sup> )       | 14.05 (19.97)±7.73  | 16.83 (8.82)±6.31      | 0.30    |
| Inital pH†                       | 7.30±1.04           | 7.25±0.19              | 0.15    |
| Beta excess* (mmol/L)            | 8.6±6.52            | 12.27±15.29            | 0.031   |
| Atrial lactate* (mmol/L)         | 3.13±1.71           | 5.12±3.53              | 0.0001  |
| Atrial lactate* (mmol/L)         | 3.14±0.75           | 5.82±3.94              | <0.0001 |
| Atrial lactate* (mmol/L)         | 3.03±1.43           | 5.97±3.53              | <0.0001 |
| Lactate clearance* (%)           | 27.93±5.09          | -23.26±7.57            | <0.0001 |


J Emerg Trauma Shock 2017;10:55-9

L Dupic JPU 2107

JAMA Pediatrics | Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

## Association Between Early Lactate Levels and 30-Day Mortality in Clinically Suspected Sepsis in Children

Halden F. Scott, MD; Lina Brou, MPH; Sara J. Deakyne, MPH; Alison Kempe, MD, MPH; Diane L. Fairclough, DrPH; Lalit Bajaj, MD, MPH



| Table 1. Population Demographic and Clinical Characteristics by Lactate Category |                                       |                                 |
|--|---------------------------------------|---------------------------------|
|  | Total Population, No. (%) of Patients | ≤ 10 mg/dL, No. (%) of Patients |
| Characteristic   |                                       |                                 |
| Age, years   |                                       |                                 |
| 0-12 (mean)  | 86.7 (27)                             | 11.0 (27)                       |
| 30-60 (mean)   | 30.6 (42)                             | 38 (36)                         |
| 61-120 (mean)  | 74.0 (36)                             | 36 (28)                         |
| Race   |                                       |                                 |
| White  | 84 (22)                               | 24 (22)                         |
| Nonwhite   | 32 (8)                                | 8 (7)                           |
| Comorbidity  |                                       |                                 |
| Diabetes   | 82 (22)                               | 71 (70)                         |
| Oncologic  | 49 (13)                               | 18 (17)                         |
| Hepatitis  | 49 (13)                               | 19 (18)                         |
| Nephrologic  | 34 (9)                                | 30 (28)                         |
| Central line present   | 22 (6)                                | 22 (24)                         |
| Habits   |                                       |                                 |
| Heavy users  | 149 (32) (16)                         | 155 (40) (37)                   |
| Smoking history  | 106 (18) (17)                         | 107 (16) (34)                   |
| Temperature, °C  | 36.7 (37.0-39.1)                      | 36.4 (37.0-39.7)                |
| Hypotension, %   | 10.0 (10.0-10.0)                      | 10.0 (10.0-10.0)                |
| Dyadic lactic acid   | 343 (83)                              | 26 (23)                         |
| Cardiovascular   | 236 (58)                              | 23 (21)                         |
| Respiratory  | 123 (30)                              | 23 (21)                         |
| Hepatic  | 111 (28)                              | 31 (33)                         |
| Renal  | 45 (12)                               | 4 (3)                           |

L Dupic JPU 2107

# MONITORING ANTIBIOTHERAPIE

|   |   |  |
|---|---|--|
| <p><b>5 min</b></p> <p>If no response, consider other causes than hypovolemia. If hypovolemic, access according to PALS.</p> <p>Begin <b>Hypotension</b> resuscitation.</p> | <p>Recognize decreased mental status and perfusion.</p> <p>Begin <b>Bradycardia</b> resuscitation.</p>  |  |
|   | <p>Begin peripheral IV/IO resuscitative infusion, preferably Epinephrine 0.05 - 0.3 µg/kg/min Use Alprost: Ketamine/HYM/OMD needed for Central Venous or Artery Access</p> <p>Titrate Epinephrine (0.05 - 0.3 µg/kg/min for Cold Shock<br/>           (Tracheal Intubation, Hypothermia, Hypovolemia, Hypotension Available)</p> <p>Titrate norEpinephrine from 0.05 µg/min and upward to reverse Warm Shock<br/>           (Tracheal Intubation &gt; 10 µg/min if Noradrenepine not available)</p> |  |
| <p><b>15 min</b></p> <p><b>Fluid refractory shock?</b></p>  |   |  |
|   | <p>Begin peripheral IV/IO resuscitative infusion, preferably Epinephrine 0.05 - 0.3 µg/kg/min Use Alprost: Ketamine/HYM/OMD needed for Central Venous or Artery Access</p> <p>Titrate Epinephrine (0.05 - 0.3 µg/kg/min for Cold Shock<br/>           (Tracheal Intubation, Hypothermia, Hypovolemia, Hypotension Available)</p> <p>Titrate norEpinephrine from 0.05 µg/min and upward to reverse Warm Shock<br/>           (Tracheal Intubation &gt; 10 µg/min if Noradrenepine not available)</p> |  |
| <p><b>60 min</b></p> <p><b>Catecholamine-resistant shock?</b></p>   | <p>If no response for Absolute Adrenal Insufficiency consider Hydrocortisone.<br/>           Use Dopper Ultrasound to PIVC to Direct Fx/Fx, Intermittent, Vasoconstrictors<br/>           Goal is normal MAP+CVP, Svo<sub>2</sub> &gt;75%, and C<sub>VP</sub> &lt; 15 L/min</p>   |  |
| <p>Normal Blood Pressure<br/>           Cold Shock<br/> <math>SvO_2 = 70\%</math> or less<br/>           on Epinephrine*</p>  | <p>Low Blood Pressure<br/>           Cold Shock<br/> <math>SvO_2 = 70\%</math> or less<br/>           on Epinephrine*</p>   | <p>Low Blood Pressure<br/>           Warm Shock<br/> <math>SvO_2 = 70\%</math> or less<br/>           on Noradrenepine*</p>  |
| <p>Brown Marmoratus Spider<br/> <math>\geq 3.3\text{ mm}^2</math> with High SVL<br/>           and/or Hemolysis<br/>           Consider Levothrombin if unresuscitated.</p> | <p>Add norEpinephrine to Epinephrine to obtain normal diastolic blood pressure. If C<sub>VP</sub> &lt; 13 mmHg add Esmolol, Enoxime, Levosimendan, or Mannitol.</p>   | <p>If epinephrine, add Vasopressin, Terlipressin, or Angiotensin. But<br/>           CI decreases below 3.3 L/min<sup>1/2</sup> and/or CVP &lt; 13 mmHg<br/>           Add Esmolol, Enoxime, Levosimendan.</p> |
| <p><b>Persistent Catecholamine-resistant shock?</b></p>   |   |  |
| <p>Evaluate Pericardial Effusion or Pneumothorax,<br/>           Maritime IAP &gt; 12mmHg</p>   |   |  |
| <p><b>Refractory Shock?</b></p>   |   |  |
| <p>ECMO</p>   |   |  |

L Dupic JPU 2017

L Dupic JPU 2107

| Table 1. Characteristics of Study Cohort                |                       |
|---|-----------------------|
| Characteristic  | Value                 |
| Age, y <sup>a</sup>                                     | 22 (17-35)            |
| Male (%)  | 73 (65)               |
| Female  | 57 (44)               |
| Height, cm <sup>b</sup>                                 | 164 (149)             |
| Weight, kg <sup>b</sup>                                 | 62 (59)               |
| BMI <sup>b</sup>  | 24 (22)               |
| Other   | 4 (3)                 |
| Unknown   | 60 (51)               |
| Obesity condition, n (%)                                |                       |
| None  | 53 (44)               |
| Overweight  | 18 (14)               |
| Thinness  | 6 (5)                 |
| Obesity risk category, n (%)                            |                       |
| Emergency department                                    | 64 (49)               |
| Primary care  | 25 (17)               |
| PICU  | 22 (17)               |
| Operating Room  | 9 (7)                 |
| Operative time, min <sup>c</sup>                        |                       |
| Median of Mortality-Y score                             | 11 (10-20)            |
| Pediatric Logistic Organ Dysfunction Score <sup>d</sup> | 11 (10-20)            |
| Baseline laboratory values, n (%)                       |                       |
| White blood cell count                                  | 103 (85-130)          |
| Hemoglobin (g/dL)                                       | 10.0 (8.0-12.0)       |
| Platelets (1,000/uL)                                    | 20,000 (5,000-35,000) |
| Creatinine (mg/dL)                                      | 0.8 (0.5-1.5)         |
| International normalized ratio                          | 1.26 (1.10-1.4)       |
| Urea (mg/dL)  | 10 (7-14)             |
| Compliance with initial resuscitation goals, n (%)      |                       |
| Antibiotics at 1 h                                      | 24 (68)               |
| Antibiotics at 2 h                                      | 66 (81)               |
| Initial resuscitation time > 60 min                     | 40 (85)               |
| Lactate measured  | 60 (65)               |
| Glucose measured, in (mg)                               | 60 (65)               |
| Measured base excess, in (mEq/L)                        | -6.6 (7.4)            |
| Measured arterial oxygen saturation, in (%)             | 93 (87)               |
| Measured arterial oxygen saturation, in (%)             | 93 (87)               |
| Measured arterial oxygen saturation, in (%)             | 93 (87)               |

## Delayed Antimicrobial Therapy Increases Mortality

## **and Organ Dysfunction Duration in Pediatric S**

Page 10 of 10

## DOSAGE ANTIBIOTIQUES

Therapeutic drug monitoring of  $\beta$ -lactams in critically ill patients:  
proof of concept  
Jason A. Roberts<sup>a,b,c,\*</sup>, Marta Ulldemolins<sup>a,d</sup>, Michael S. Roberts<sup>e,f</sup>, Brett McWhinney<sup>g</sup>,  
Jacobus Ungerer<sup>h</sup>, David L. Paterson<sup>b,i</sup>, Jeffrey Lipman<sup>a,c</sup>

Etude prospective  
236 patients sur 11 mois  
11  $\beta$ -lactamines  
Dosage 2 fois la 1<sup>ère</sup> semaine  
Cmax >10 CMI

12 % d' échec clinique de traitement  
Mais  
Pas de relation entre  
PD targets et outcomes cliniques

Posologie maintenue 26 %  
Posologie augmentée 51 %  
Posologie diminuée 23 %

Int J Antimicrob Agents 2010


L Dupic JPU 2107

## MONITORING BIOLOGIQUE

L Dupic JPU 2107

### Accuracy of serum procalcitonin for the diagnosis of sepsis in neonates and children with systemic inflammatory syndrome: a meta-analysis

Giuseppe Pontrelli<sup>1</sup>, Franco De Crescenzo<sup>1,2</sup>, Roberto Buzzetti<sup>3</sup>, Alessandro Jenkner<sup>1,3</sup>, Sara Baldazzi<sup>4</sup>,  
Francesca Gallo Carlucci<sup>5</sup>, Domenico Amodeo<sup>6</sup>, Mara De Luca<sup>7</sup>, Sara Chiarchi<sup>8</sup>, Elisa Hof-David<sup>9</sup>, Giorgia Copponi<sup>10</sup>,  
Alessandro Simeoni<sup>11</sup>, Elena Ferretti<sup>12</sup>, Valeria Us-Franco<sup>13</sup>, Virginia Rau<sup>14</sup>, Martina Delia Corle<sup>15</sup>, Luca Grammatici<sup>16</sup>,  
Marco Ciabattoni<sup>17</sup>, Stefania Lovadina<sup>18</sup> and Paola Rossi<sup>19</sup>



**Conclusions:** PCT shows a moderate accuracy for the diagnosis of sepsis in neonates with suspected sepsis at the cut-off of 0.25 ng/ml. More studies with high methodological quality are warranted, particularly in neonates; studies considering EOS and LOS separately are needed to improve specificity.

L Dupic JPU 2107

Accuracy of a real-time continuous glucose monitoring system in children with septic shock: A pilot study  
Sumanth Prabhudesai, Amruta Kanjani,<sup>1</sup> Isha Bhagat,<sup>2</sup> Karnam G. Ravikumar,<sup>3</sup> and Bala Ramachandran<sup>3</sup>

#### Results:

Nineteen children were included, and 235 pairs of BG-CGMS readings were obtained. BG and CGMS had a correlation coefficient of 0.61 ( $P < 0.001$ ) and a median relative absolute difference of 17.29%.

#### Conclusion:


CGMS provides a fairly accurate estimate of BG in children with septic shock. It is unaffected by a variety of clinical variables. The accuracy over extremes of blood sugar may be a concern. We recommend larger studies to evaluate its use for the early detection of hypoglycemia and hyperglycemia.

I JCC 2016

L Dupic JPU 2107

## MONITORING IMMUNOLOGIQUE

L Dupic JPU 2107





## CONCLUSION

### MONITORAGE CHOC SEPTIQUE

CLINIQUE

MONITORING HEMODYNAMIQUE MULTIMODAL

Clairance lactate

Dosage des antibiotiques

TEMPS

MERCI DE VOTRE ATTENTION

L Dupic JPU 2107


L Dupic JPU 2107



[laurent.dupic@aphp.fr](mailto:laurent.dupic@aphp.fr)

L Dupic JPU 2107

L Dupic JPU 2107



L Dupic JPU 2017

### American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock

Recognition Bundle (see AAP Trigger tool example Figure 2)

- Screen patient for septic shock using an institution trigger tool
- Clerical documentation within 15 minutes for any patient who screens positive in the trigger
- Initiate Resuscitation Bundle within 15 minutes for patient identified by the trigger tool informed the assessing clinician of concern/suspicion of septic shock

Resuscitation Bundle (see Algorithm Figure 3 and 4)

- Establish I&O access within 5 minutes.
- Appropriate fluid resuscitation begun within 30 minutes.
- Begin antibiotic therapy within 60 minutes.
- Begin peripheral or central intravenous infusion therapy for fluid-refractory shock within 60 minutes.

Stabilization-Bundle (see Algorithm Figure 3 and 4)

- Use multimodal monitoring to optimize fluid, hormonal and cardiovascular therapies to attain hemodynamic goals
- Continuously reassess need for appropriate antimicrobial therapy and source control

Performance Bundle

- Measure adherence to Trigger, Resuscitation, and Stabilization Bundles
- Perform root cause analysis to identify barriers to adherence
- Provide an action plan to address identified barriers

CCM 2017

L Dupic JPU 2017

**American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock**

**Therapeutic Endpoints (Level 1C)**

- Capillary refill less than or equal to 2 seconds, normal pulses with no differential between peripheral and central pulses, warm extremities, urine output greater than 1 mL/kg/hr, normal mental status, and normal blood pressure for age
- greater than 95% Sa<sub>O</sub>
- less than 5% difference in preductal and postductal Sa<sub>O</sub>
- ScVO<sub>2</sub> greater than 70%
- Absence of right-to-left shunting, tricuspid regurgitation, or right ventricular failure on echocardiographic analysis.
- Normal glucose and ionized calcium concentrations
- SVC flow greater than 40 mL/kg/min
- CI greater than 3.3 L/min/m<sup>2</sup>
- Normal INR
- Normal anion gap, and lactate Fluid overload less than 10%

CCM 2017

L Dupic JPU 2017

**American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock**

**Fluid refractory shock?**

If no response to fluid resuscitation, initiate Epinephrine 0.03–0.3 µg/kg/min  
Begin dopamine 10–20 µg/kg/min if epinephrine not available  
Use Dopexamine 0.02–0.04 µg/kg/min if epinephrine and dopamine not available  
If no response to dopamine, consider norepinephrine  
Goal is normotensive MAP >90 mmHg and O<sub>2</sub> saturation >95%.

**Catecholamine-resistant shock?**

If no response to dopamine, consider norepinephrine  
Use Dopexamine 0.02–0.04 µg/kg/min if epinephrine and dopamine not available  
Goal is normotensive MAP >90 mmHg and O<sub>2</sub> saturation >95%.

**Persistent Catecholamine-resistant shock?**

If no response to dopamine, consider norepinephrine  
Use Dopexamine 0.02–0.04 µg/kg/min if epinephrine and dopamine not available  
Goal is normotensive MAP >90 mmHg and O<sub>2</sub> saturation >95%.

**Refactory Shock?**

Evaluate Peripheral Edema or Pneumothorax, Monitor AP + Urine Output

CCM 2017

L Dupic JPU 2017

**American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock**

**Monitoring (Level 1C)**

- Pulse oximetry
- Arterial pH Continuous ECG
- Continuous intra-arterial blood pressure
- Temperature
- Glucose and calcium concentration
- Ins and outs, urine output
- CVP/oxygen saturation
- CO
- SVC flow
- INR
- Anion gap and lactate

CCM 2017

L Dupic JPU 2017

**Multimodal Monitoring for Hemodynamic Categorization and Management of Pediatric Septic Shock: A Pilot Observational Study\***

Sachittha Ranjit, MD, FCCM<sup>1</sup>; Gramann Arun, MD, FNIBP<sup>2</sup>; Nitinam Klossow, MBBS, FAAP<sup>3</sup>; FCCM<sup>4</sup>; Mbd Kashif Ali, MBBS<sup>5</sup>; Rajeshwari Natraj, FNP<sup>6</sup>; Sharad Shresti, MD<sup>7</sup>; Indira Jayakumar, DCH, DNB<sup>8</sup>; Deepika Gandhi, DNB<sup>9</sup>

| Shock category | Atrial blood (mL) |              |               |              |              | Wrist blood (mL) |               |              |              |              | Total (mL)   |
|----------------|-------------------|--------------|---------------|--------------|--------------|------------------|---------------|--------------|--------------|--------------|--------------|
|                | Shock resolved    | Nonresolving | Nonresponding | Nonimproving | Nonimproving | Nonresolving     | Nonresponding | Nonimproving | Nonimproving | Nonimproving |              |
| Outcome        |                   |              |               |              |              |                  |               |              |              |              |              |
| Shock resolved | 11/11             | —            | —             | —            | —            | 10/10            | —             | —            | —            | —            | 40/40 (100%) |
| Survived       | 11/11             | 5/10         | —             | —            | —            | 10/11            | —             | —            | —            | —            | 44/48 (91%)  |
| Died           | —                 | —            | —             | —            | —            | —                | —             | —            | —            | —            | —            |
| Shock resolved | —                 | —            | —             | —            | —            | —                | —             | —            | —            | —            | —            |
| Survived       | —                 | —            | —             | —            | —            | —                | —             | —            | —            | —            | —            |
| Died           | —                 | —            | —             | —            | —            | —                | —             | —            | —            | —            | —            |

\*Sensitivity = true positives / (true positives + false positives); Specificity = true negatives / (true negatives + false negatives). NPV = negative predictive value; PPV = positive predictive value.

†BP = blood pressure, ECHO = echocardiography, AC = arterial wave form, SF = soft systolic, MF = mean arterial blood pressure.

‡Nonimproving shock = shock that did not improve after initial resuscitation with fluids and vasopressors.

§Nonresponding shock = shock that did not respond to initial resuscitation with fluids and vasopressors.

¶Nonresolving shock = shock that did not resolve after initial resuscitation with fluids and vasopressors.

\*\*Shock described if central venous oxygen saturation (ScvO<sub>2</sub>) remained > 50% and perfusion was stable.

††Shock described if central venous oxygen saturation (ScvO<sub>2</sub>) remained < 50% and perfusion was unstable.


‡‡Shock described if central venous oxygen saturation (ScvO<sub>2</sub>) remained < 50% and at least 4 of the following metrics had a normal or low value: carboxyhemoglobin, creatinine, arterial monitoring, and bedside ECHO findings.

**Lactate clearance as the predictor of outcome in pediatric septic shock**

Richa Choudhary, Sadasivam Sitaraman, and Anita Choudhary

| Variable                           | Sensitivity | Specificity | PPV | NPV | OR    | 95%CI     |
|------------------------------------|-------------|-------------|-----|-----|-------|-----------|
| Lactate 1 (10 mmol/L) <sup>a</sup> | 52          | 82          | 82  | 51  | 2.432 | 1.02-5.92 |
| Lactate 2 (10 mmol/L)              | 62          | 87          | 89  | 56  | 4.634 | 2.67-8.58 |
| Lactate 3 (10 mmol/L)              | 60          | 95          | 81  | 75  | 4.495 | 2.95-7.28 |

<sup>a</sup>For each lactate increase in lactate as ROC Curve, OR = Odds Lactate At Two Lactate Above Test Cut-off Ratio, CI = Confidence Interval, PPV = Positive Predictive Value, NPV = Negative Predictive Value, OR = Odds Ratio




J Emerg Trauma Shock 2017;10:55-9

L Dupic JPU 2017

**Validation of lactate clearance at 6 h for mortality prediction in critically ill children**

Rajeev Kumar and Nirmal Kumar

| lactate clearance test    |                  |       | Mortality   |                  |       |
|---------------------------|------------------|-------|-------------|------------------|-------|
| Died (n=23)               | Survived (n=117) | Total | Died (n=23) | Survived (n=117) | Total |
| <16.435 (n=46)            | 19               | 29    | 46          | 88               | 134   |
| >16.435 (n=92)            | 4                | 88    | 92          | 117              | 210   |
| Total                     | 23               | 117   | 140         |                  |       |
| sensitivity               |                  |       | 82.6%       |                  |       |
| specificity               |                  |       | 75.2%       |                  |       |
| Positive predictive value |                  |       | 39.6%       |                  |       |
| Negative predictive value |                  |       | 95.7%       |                  |       |



Indian J Crit Care Med. 2016 Oct; 20(10): 570-574.

L Dupic JPU 2017

Multimodal monitoring for hemodynamic categorization and management of pediatric septic shock: a pilot observational study\*.  
Ranjit S<sup>1</sup>, Aram G, Kissoon N, Ali MK, Natraj R, Shresti S, Jayakumar I, Ga

**CONCLUSION:**

**Bedside echocardiography provided crucial information leading to the recognition of septic myocardial dysfunction and uncorrected hypovolemia** that was not apparent on clinical assessment. With invasive blood pressure monitoring, echocardiography affords a simple noninvasive tool to determine the cause of low cardiac output and the physiological basis for adjustment of therapy in patients who remain in shock despite 40 mL/kg fluid.

PCCM 2014

---

L Dupic JPU 2017